Circulating thymidine kinase activity predicts survival and optimal treatment sequencing in BRAF-mutated metastatic melanoma in the SECOMBIT trial.

Helgadottir H, Capone M, Ridolfi L, Zambelli A, Piccin L, Gogas H, Tucci M, Quaglino P, Del Vecchio M, Minisini AM, Spagnolo F, Rutkowski P, Ferraresi V, Arance A, Guida M, Maiello E, Lebbé C, Bulgarelli J, Chiarion Sileni V, Paone M, Melero I, Trojaniello C, Bergqvist M, Dummer R, Giannarelli D, Palmieri G, Ascierto PA

Open source

DOI: 10.1158/1078-0432.ccr-26-1402
Published: 2026 Aug 4
Container: Clinical cancer research : an official journal of the American Association for Cancer Research
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1158/1078-0432.ccr-26-1402,
  title = {Circulating thymidine kinase activity predicts survival and optimal treatment sequencing in BRAF-mutated metastatic melanoma in the SECOMBIT trial.},
  author = {Helgadottir H and Capone M and Ridolfi L and Zambelli A and Piccin L and Gogas H and Tucci M and Quaglino P and Del Vecchio M and Minisini AM and Spagnolo F and Rutkowski P and Ferraresi V and Arance A and Guida M and Maiello E and Lebbé C and Bulgarelli J and Chiarion Sileni V and Paone M and Melero I and Trojaniello C and Bergqvist M and Dummer R and Giannarelli D and Palmieri G and Ascierto PA},
  year = {2026},
  journal = {Clinical cancer research : an official journal of the American Association for Cancer Research},
  doi = {10.1158/1078-0432.ccr-26-1402},
  url = {https://doi.org/10.1158/1078-0432.ccr-26-1402}
}

RIS

TY  - JOUR
TI  - Circulating thymidine kinase activity predicts survival and optimal treatment sequencing in BRAF-mutated metastatic melanoma in the SECOMBIT trial.
AU  - Helgadottir H
AU  - Capone M
AU  - Ridolfi L
AU  - Zambelli A
AU  - Piccin L
AU  - Gogas H
AU  - Tucci M
AU  - Quaglino P
AU  - Del Vecchio M
AU  - Minisini AM
AU  - Spagnolo F
AU  - Rutkowski P
AU  - Ferraresi V
AU  - Arance A
AU  - Guida M
AU  - Maiello E
AU  - Lebbé C
AU  - Bulgarelli J
AU  - Chiarion Sileni V
AU  - Paone M
AU  - Melero I
AU  - Trojaniello C
AU  - Bergqvist M
AU  - Dummer R
AU  - Giannarelli D
AU  - Palmieri G
AU  - Ascierto PA
PY  - 2026
JO  - Clinical cancer research : an official journal of the American Association for Cancer Research
DO  - 10.1158/1078-0432.ccr-26-1402
UR  - https://doi.org/10.1158/1078-0432.ccr-26-1402
ER  -

APA

H, H., M, C., L, R., A, Z., L, P., H, G., M, T., P, Q., M, D. V., AM, M., F, S., P, R., V, F., A, A., M, G., E, M., C, L., J, B., V, C. S., M, P., I, M., C, T., M, B., R, D., D, G., G, P., & PA, A. (2026). Circulating thymidine kinase activity predicts survival and optimal treatment sequencing in BRAF-mutated metastatic melanoma in the SECOMBIT trial.. Clinical cancer research : an official journal of the American Association for Cancer Research. https://doi.org/10.1158/1078-0432.ccr-26-1402

Source records

pubmed · retrieved 2026-09-26T21:25:31.994Z